Ultra-Long-Acting MPT In-situ Forming Implant (ISFI)
First-in-line, ultra-long-acting injectable MPT that offers durable and sustained protection from HIV transmission, high efficacy of contraception, increased user compliance, and the ability to be removed. It consists of a liquid MPT formulation utilizing excipients that form a biodegradable depot after subcutaneous injection (in-situ forming implant (ISFI)).
Development Stage:
Preclinical – Early (Pre1)
Hormonal/Non-Hormonal:
Hormonal
Delivery Route & Method:
Systemic - Injectable In-situ Forming Implant (Subcutaneous)
Developer:
- University of North Carolina, Chapel Hill
Funding:
- Nat. Institute Allergy & Infect. Diseases (NIAID)
Funding Mechanism:
NIAID: R01
Past Funding:
NIAID
Active Ingredient(s):
- Hormonal Contraceptive
- Antiretroviral (ARV)
Product Indication(s):
- HIV
- Pregnancy
Useful Links:
- https://reporter.nih.gov/search/WcUn8fWZy0KhTneo0yrZJQ/project-details/10258079
- https://benhabbour.web.unc.edu/
- https://news.unchealthcare.org/2021/04/benhabbour-receives-3-74-million-to-create-injectable-technology-for-contraception-hiv-prevention/
- https://www.newswise.com/articles/unc-researchers-receive-3-74-million-to-create-injectable-technology-for-contraception-hiv-prevention?sc=rsgt